These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 18388148

  • 1. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 2. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A, Barceló M, Erra A, Palacio C, Marsal S.
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [Abstract] [Full Text] [Related]

  • 3. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A, Arnaud B, Marrote H, Cazalis MA, Diasparra J, Gouraud A, Mougin B, Miossec P.
    J Rheumatol; 2007 Nov; 34(11):2158-61. PubMed ID: 17896807
    [Abstract] [Full Text] [Related]

  • 4. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [Abstract] [Full Text] [Related]

  • 5. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 6. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [Abstract] [Full Text] [Related]

  • 7. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [Abstract] [Full Text] [Related]

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 9. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 10. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT, Collins CE, Yang HT, Migone TS, Stohl W.
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [Abstract] [Full Text] [Related]

  • 11. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

  • 12. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 Jun; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

  • 13. Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis.
    Sugihara M, Tsutsumi A, Suzuki E, Wakamatsu E, Suzuki T, Ogishima H, Hayashi T, Chino Y, Ishii W, Mamura M, Goto D, Matsumoto I, Ito S, Sumida T.
    Arthritis Rheum; 2007 Jul; 56(7):2160-9. PubMed ID: 17599736
    [Abstract] [Full Text] [Related]

  • 14. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 15. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
    Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O.
    Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
    [Abstract] [Full Text] [Related]

  • 16. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity.
    Kawashima M, Miossec P.
    Ann Rheum Dis; 2005 Mar; 64(3):415-8. PubMed ID: 15286007
    [Abstract] [Full Text] [Related]

  • 17. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J.
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [Abstract] [Full Text] [Related]

  • 18. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [Abstract] [Full Text] [Related]

  • 19. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [Abstract] [Full Text] [Related]

  • 20. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.